title: Alternating treatment with S-1 plus low-dose cisplatin and S-1 alone for advanced gastric cancer.
abstract: BACKGROUND
  The aim of this study was to investigate the efficacy and safety of an alternating regimen of S-1 plus low-dose cisplatin and S-1 alone as adjuvant therapy in patients with advanced gastric cancer.
  
  
  METHODS
  The study group comprised 100 patients with stage IIIA, stage IIIB, or stage IV. Patients postoperatively received three 5-week cycles of chemotherapy. In the first cycle, S-1 (80 mg/m(2)) was given daily for 3 weeks, followed by 2 weeks of rest, and low-dose cisplatin (10 mg) was given on days 1 to 5 and 8 to 12. In the second and third 5-week cycles, S-1 alone was given. The primary endpoints were median survival time, and survival at 1 and 3 years. Secondary endpoints were safety and overall response rates.
  
  
  RESULTS
  Median survival time was 18 months in stage IV and 32 months in stage IIIB. The rates of survival at 1 and 3 years were 68.7% and 30.6% in stage IV, 100% and 68.4% in stage IIIA, and 100% and 46.6% in stage IIIB, respectively. Adverse events of grade 3 or 4 occurred in 14% of the patients. The overall response rate of target lesions was 54%.
  
  
  CONCLUSIONS
  Our regimen is effective and safe for adjuvant therapy in patients with curatively resected stage III gastric cancer.
authors.affiliation: Department of Surgery, Shin-Tokyo Hospital, 473-1 Nemoto, Matsudo, Chiba, Japan. k-mita@sth-medical.co.jp
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Mita
authors.forename: Hideto
authors.initials: H
authors.lastname: Ito
authors.forename: Masato
authors.initials: M
authors.lastname: Fukumoto
authors.forename: Ryo
authors.initials: R
authors.lastname: Murabayashi
authors.forename: Kazuya
authors.initials: K
authors.lastname: Koizumi
authors.forename: Takashi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kikuchi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kagaya
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015996:Survival Rate / Q000639:trends; D005641:Tegafur / Q000008:administration & dosage*; D013997:Time Factors; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin